Celldex Therapeutics Inc. (NASDAQ:CLDX): Zacks View on 1Q14 Earnings and Pipeline Update

520

Dallas, Texas 05/12/2014 (FINANCIALSTRENDS) –Celldex Therapeutics, Inc. (NASDAQ:CLDX) recently announced its 1Q14 earnings on May 1, 2014 where it posted more than expected losses of $0.33 per share, wider than 1Q13 losses of $0.23 per share. The 1Q14 losses also missed Zacks Consensus Estimate of $0.26 per share. However, 1Q14 revenues were reported at $0.4 million, 82.8% down from 1Q13 and better than Zack Consensus Estimate of nil. The decline in revenue was largely because of lower royalties on Rotarix from GlaxoSmithKline plc (ADR) (NYSE:GSK) because of its termination of agreement with Glaxo.

1Q14 Details:

Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s 1Q14 research and development expenses increased 92.1% to $27.1 million when compared with 1Q13. This was largely attributed to development of glembatumumab vedotin and rindopepimut as well as expansion of varlilumab related study.

The company also reported 46% year over year increase in its 1Q14 general and administrative expenses because of higher cost of professional services, personnel related expenses as well as commercial planning costs for glembatumumab vedotin and rindopepimut.

2 H 14 Outlooks:

Celldex Therapeutics, Inc. (NASDAQ:CLDX) also provided an update on its pipeline products along with 1Q14 earnings release. The company noted that it expects continues patient enrolment for its Phase-III study on rindopepimut which is expected to be completed by mid-2014. The study is testing the potential use of drug for positive glioblastoma multiform (GBM). Moreover the company is also enrolling patients for its rindopepimut related Phase-II study for recurrent GBM and it expects the study to be completed by end of 2014.

Moreover, the company also expects to begin Phase-II studies for squamous cell lung cancer and metastatic melanoma including glembatumumab vedotin.

On Friday, Celldex Therapeutics’ stock gained 15.33% and closed at $12.79. However, the stock plunged 11.85% in overall, during the last week. At its previous close, the stock is about 67% below its 52 week high of $38.84 and just about 16% above its 52 week low of $11.02.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.